Full-Time

Staff Product Manager

AI & Research

Posted on 11/26/2024

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

Compensation Overview

$125k - $180kAnnually

+ Incentive Compensation + Restricted Stock Units

Senior, Expert

Company Historically Provides H1B Sponsorship

Chicago, IL, USA

Hybrid role requiring some in-office presence.

Category
Product Management
Product Research
Product Strategy
Product
Required Skills
Agile
Product Management
Machine Learning
JIRA
Requirements
  • 5-10 years of technical experience building software in the tech or biotech industry
  • Experience with AI or ML product development, from concept to launch, preferably in a consumer-facing technology company
  • Experience recognizing customer needs, creating an encapsulating product vision, translating requirements to product specifications, driving alignment with stakeholders, building and bringing products to market, and driving adoption post-launch
  • Experience working with agile software development teams
  • A history of building and using product analytics to drive decisions
  • Experience with software development and project management tools (JIRA, Trello, etc.)
  • Ability and interest to quickly ramp up on new concepts in the fields of genomics, oncology, and cardiology
  • Excellent written and verbal communication skills, including the ability to act as translator among diverse teams of biologists, medical professionals, engineers, operators, and data scientists.
Responsibilities
  • Understand current product gaps in our AI & Research portfolio
  • Identify opportunities and define the early AI & Research concepts for exploration
  • Manage the portfolio of AI & Research ideas and products in incubation, and initiate pilot programs for new features to validate ideas/concepts
  • Manage allocation of AI & Research team capacity: where we should embed data scientists in product teams vs where we should allocate capacity to idea incubation
  • Act as an advocate and consultant for AI capabilities, helping translate complex technical concepts into actionable product features
  • Understand how AI models are being utilized by product teams and implement feedback loops to gather insights on product performance, usability and areas for enhancement
  • Manage prioritization and execution of programs in development
  • Represent and communicate product vision to the technology leaders and other senior executives.

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Additionally, Tempus conducts research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling tumor DNA. The company generates revenue by charging healthcare providers and companies for access to its platform and insights.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus secured $560 million in debt financing to support growth and acquisitions.
  • Partnerships with Stemline and Artera expand Tempus' AI platform applications.
  • The launch of the Olivia app empowers patients with AI-driven health management.

What critics are saying

  • High debt levels may strain Tempus' financial stability if revenue targets aren't met.
  • Increased competition from AI healthcare platforms could erode Tempus' market share.
  • Regulatory challenges in AI and data privacy could impact Tempus' operations.

What makes Tempus unique

  • Tempus uses AI to provide personalized treatment insights for cancer patients.
  • Their platform integrates clinical and molecular data for precision medicine.
  • Tempus' AI-driven liquid biopsy assay enhances cancer detection and profiling.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Business Wire
Feb 25th, 2025
Ares Management Upsizes Tempus Debt Facilities to $560 Million

Combined with $260 million of capital provided in 2022 and 2023, Ares Credit funds have provided Tempus a total debt package of approximately $560 million.

Pulse 2.0
Feb 24th, 2025
Tempus Secures $560M Debt Financing

Ares Management announced that Ares Credit funds provided $300 million in additional debt financing to Tempus AI, bringing the total debt package to $560 million. This financing supports Tempus' acquisition of Ambry Genetics, completed on February 3, 2025. Ares praised Tempus' growth strategy and AI-enabled solutions in medicine. Tempus' CFO, Jim Rogers, expressed appreciation for Ares' investment, which aids in enhancing healthcare technology and patient outcomes.

Hit Consultant
Feb 21st, 2025
Stemline Therapeutics To Deploy Tempus Next’S Ai-Enabled Care Pathway Intelligence Platform

Stemline Therapeutics to Deploy Tempus Next’s AI-Enabled Care Pathway Intelligence Platform. by Fred Pennic 02/21/2025 Leave a Comment. What You Should Know: – Tempus, a provider of AI-driven precision medicine, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group announced a new collaboration to improve the use of ESR1 testing in metastatic breast cancer (mBC). – The partnership will leverage Tempus’ Next platform, an AI-enabled care pathway intelligence tool, to help clinicians determine when ESR1 testing may be appropriate for their patients.Challenges in ESR1 TestingESR1 mutations are a critical factor in the progression of ER+/HER2- mBC, a common type of breast cancer. Up to 50% of patients with this type of cancer can develop ESR1 mutations after prior endocrine therapy. Recognizing this, the American Society of Clinical Oncology (ASCO) recommends ESR1 mutation testing at each disease progression. Tempus Next: Guiding Clinical DecisionsTempus’ Next platform will analyze clinical data from mBC patients and notify clinicians when ESR1 testing is missing at disease progression

ETF Daily News
Feb 15th, 2025
Apollon Wealth Management LLC Makes New $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM)

Apollon Wealth Management LLC makes new $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM).

Money Morning
Feb 14th, 2025
Nancy Pelosi's Favorite AI Stock Rising Again After 13% Surge

Tempus announced yesterday that it was collaborating with the nonprofit Institute for Follicular Lymphoma Innovation to develop treatment options for patients with the disease.

INACTIVE